March 17, 2020 / 5:37 PM / 2 months ago

BRIEF-Ribomic Enters License Agreement With Aju Pharma For Rbm-007 In Age-Related Macular Degeneration

March 17 (Reuters) - Ribomic Inc:

* RIBOMIC ENTERS LICENSE AGREEMENT WITH AJU PHARMA FOR RBM-007 IN AGE-RELATED MACULAR DEGENERATION

* RIBOMIC - UPON EXECUTION OF AGREEMENT, AJU WILL OBTAIN EXCLUSIVE LICENSE TO DEVELOP AND SELL PRODUCT CONTAINING RBM-007 IN TERRITORY

* RIBOMIC - WILL RECEIVE AN UPFRONT PAYMENT OF US$1 MILLION AND IS ELIGIBLE FOR POTENTIAL DEVELOPMENT MILESTONE PAYMENTS OF UP TO US$5 MILLION

* RIBOMIC- WILL SUPPLY PRODUCT TO AJU AT PRODUCT SUPPLY PRICES, WHICH INCLUDES ROYALTIES, FOR AJU’S SALE OF PRODUCT IN TERRITORY

* RIBOMIC - RBM-007 IS CURRENTLY BEING EVALUATED IN A PHASE 2 STUDY Source text: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below